Sidra Medicine unveils Qatar’s first advanced gene-editing therapy for blood disorders

On 2026-04-22, Sidra Medicine unveiled the availability of Casgevy, Qatar’s first advanced CRISPR/Cas9 gene-editing therapy for blood disorders. The treatment was approved by Qatar’s Ministry of Public Health, alongside reference approvals by the US FDA and European Medicines Agency, and is intended for sickle cell disease and transfusion-dependent thalassemia patients in Qatar.